The 12 mg Phase 2 arm had an estimated mean weight reduction of 24.2% at 48 weeks. The sponsor’s TRIUMPH-1 efficacy analysis reported a 28.3% mean reduction at 80 weeks in its 12 mg arm.
Two studies and two time points
Both estimates compare groups assigned within their own protocols. The longer duration and differences in the study populations and analysis affect the interpretation.
How to interpret the evidence
Read each result next to its placebo value and time point. Neither percentage gives a personal expected response.
This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.